InvestorsHub Logo
Followers 9
Posts 540
Boards Moderated 0
Alias Born 01/26/2014

Re: None

Sunday, 11/16/2014 8:23:31 PM

Sunday, November 16, 2014 8:23:31 PM

Post# of 3806
I've been thinking over the recent release of information from cohort 3 and the plans to move on to phase 2. I was originally disappointed that phase 2 wasn't going to begin until 2nd quarter 2015 and I've heard others voice the same disappointment. But then I was thinking, they need to finish out this cohort (without enrolling any new participants) and report on data. That will probably happen by EOY. I'm sure there are some decisions to finalize on trial design and setup. It doesn't seem too out of range for that to take a month or two, plus the task of getting all Dr's and protocols in the trial "on the same page" across multiple locations. If I think of it that way, April isn't too far off. I wonder too if there may be a little more sensitivity to meeting shareholder expectations (not over promising with the risk of under delivering), and that maybe they are giving themselves a little breathing room. Have to wait and see, I guess.

I hope the final results from cohort 3 will share a little more data and give us a little more of a peek at trial design for phase 2 and firmer dates. With that said, I think it's pretty impressive that GALT is aiming as high as they are in targeting cirrhotic patients for the upcoming trial. Measuring HPV pressure as an indicator of efficacy is really interesting too. If that shows significant reduction, I would think we would really have something. The complications from increased HPV pressure are some of the greatest survival risks to cirrhotic patients. I wonder too if longer courses of treatment might be included in the phase 2 design?

I'm sure it's going to be a while, but It'd be great to hear news of the melanoma combo study with Yervoy. Especially after the recent news of BMY signing an agreement with Galecto--seems like there must be something going on there.

IMO, exciting times ahead, at the current prices, I'm willing to risk a few more of my hard earned dollars as I can see the potential reward being substantial.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News